Cloud-clone
SKU(재고 관리 코드):PAA145Hu01
Polyclonal Antibody to Vascular Endothelial Growth Factor C (VEGFC)
Polyclonal Antibody to Vascular Endothelial Growth Factor C (VEGFC)
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.
Product No.
PAA145Hu01
Organism Species
Homo sapiens (Human)
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPA145Hu01-Recombinant Vascular Endothelial Growth Factor C (VEGFC)
Buffer Formulation
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Traits
Liquid
Concentration
500µg/mL
Organism Species More
Mus musculus (Mouse)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against VEGFC. It has been selected for its ability to recognize VEGFC in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Journal of Cellular Biochemistry | Alternatively activated RAW264. 7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma PubMed: 19241443 |
| genetics and molecular research | Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages PubMed: 26125824 |
| Experimental and Therapeutic | Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia PubMed: 26622498 |
| Am J Pathol | IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages PubMed: 26608451 |
| PLoS One. | Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. pubmed:27383632 |
| Oncology Letters | RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth andinduces apoptosis in mouse breast cancer in vitro and in vivo. pubmed:27895746 |
| Angiogenesis | Characterization of isolated liver sinusoidal endothelial cells for liver bioengineering Pubmed:29582235 |
| Oncology Reports | Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cells Pubmed:29328465 |
| LABORATORY INVESTIGATION | Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney disease Pubmed: 31019289 |
| Cutaneous and Ocular Toxicology | Isotretinoin does not alter VEGF-A and VEGF-C levels: Do retinoids behave differently in dose-dependent and/or in vivo/in vitro conditions? Pubmed: 32722957 |
Share
